AR082653A1 - Composicion farmaceutica topica que comprende heparina - Google Patents

Composicion farmaceutica topica que comprende heparina

Info

Publication number
AR082653A1
AR082653A1 ARP110101566A ARP110101566A AR082653A1 AR 082653 A1 AR082653 A1 AR 082653A1 AR P110101566 A ARP110101566 A AR P110101566A AR P110101566 A ARP110101566 A AR P110101566A AR 082653 A1 AR082653 A1 AR 082653A1
Authority
AR
Argentina
Prior art keywords
heparina
topica
pharmaceutical composition
pharmaceutical formulation
formulation according
Prior art date
Application number
ARP110101566A
Other languages
English (en)
Inventor
Michele Virno
Original Assignee
Advance Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082653(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Advance Holdings Ltd filed Critical Advance Holdings Ltd
Publication of AR082653A1 publication Critical patent/AR082653A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Formulación farmacéutica tópica caracterizada porque comprende una solución de heparina, y por lo menos, un éster polioxialquileno de un hidroxiácido graso.Reivindicación 4: Formulación farmacéutica de acuerdo con la reivindicación 3, caracterizada porque dicha solución acuosa comprende además, por lo menos, un alcohol. Reivindicación 8: Formulación farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes, para el tratamiento o la prevención de una complicación funcional de fístulas A-V y de injertos A-V en pacientes sometidos a hemodiálisis crónica.
ARP110101566A 2010-05-07 2011-05-06 Composicion farmaceutica topica que comprende heparina AR082653A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2010A000816A IT1400232B1 (it) 2010-05-07 2010-05-07 Composizione farmaceutica topica comprendente eparina
US34762610P 2010-05-24 2010-05-24

Publications (1)

Publication Number Publication Date
AR082653A1 true AR082653A1 (es) 2012-12-26

Family

ID=43567710

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101566A AR082653A1 (es) 2010-05-07 2011-05-06 Composicion farmaceutica topica que comprende heparina

Country Status (17)

Country Link
US (1) US20130102564A1 (es)
EP (1) EP2566457A1 (es)
JP (1) JP2013525505A (es)
KR (1) KR20130054286A (es)
CN (1) CN102946862A (es)
AR (1) AR082653A1 (es)
AU (1) AU2011250005B2 (es)
BR (1) BR112012028434A2 (es)
CA (1) CA2798116A1 (es)
CL (1) CL2012003090A1 (es)
EA (1) EA026568B1 (es)
IL (1) IL222790A0 (es)
IT (1) IT1400232B1 (es)
MX (1) MX2012012930A (es)
NZ (1) NZ603476A (es)
WO (1) WO2011138262A1 (es)
ZA (1) ZA201208949B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120009136A1 (en) * 2010-07-09 2012-01-12 The Dial Corporation Antiperspirant products comprising natural phospholipids and methods for manufacturing the same
AP2016009350A0 (en) 2014-02-10 2016-07-31 Troikaa Pharmaceuticals Ltd Topical formulations of heparin
PL229532B1 (pl) * 2014-05-29 2018-07-31 Lipolek Spolka Z Ograniczona Odpowiedzialnoscia Żelowy preparat soli sodowej heparyny do podawania naskórnego

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU77562A1 (de) * 1977-06-17 1979-03-26 Ciba Geigy Ag Verfahren zur herstellung von neuen pharmazeutischen praeparaten
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
WO1996010389A1 (de) 1994-09-30 1996-04-11 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Pharmazeutische zusammensetzung
US5668119A (en) 1996-02-22 1997-09-16 Medenica; Rajko D. Topical pharmaceutical containing heparin and method of treatment
AU754936B2 (en) * 1996-11-27 2002-11-28 Aventis Pharmaceuticals Inc. Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound
EP1189663A2 (en) * 1999-03-11 2002-03-27 Du Pont Pharmaceuticals Company Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders
NZ527046A (en) * 2001-01-16 2005-06-24 Vascular Therapies Llc A flexible cylindrical matrix material, preferably collagen with an antiproliferative agent preferably rapamycin dispersed throughout for implantation to be in contact with a vascular structure
CA2438707A1 (en) * 2001-02-16 2002-08-22 Akihiro Matsuura Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
BRPI0101486B1 (pt) * 2001-04-17 2017-09-19 Cristália Produtos Químicos Farmacêuticos Ltda. Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns
WO2003066859A2 (en) * 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
JP2007504918A (ja) 2003-09-12 2007-03-08 マリン ポリマー テクノロジーズ，インコーポレーテッド 血液透析患者における血管アクセスの保存
US20050136103A1 (en) * 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
JP6002385B2 (ja) * 2008-09-12 2016-10-05 クリティカル ファーマシューティカルズ リミテッドＣｒｉｔｉｃａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ 医薬組成物、医薬組成物における吸収促進剤の使用方法、及び医薬組成物の製造方法

Also Published As

Publication number Publication date
BR112012028434A2 (pt) 2019-09-24
JP2013525505A (ja) 2013-06-20
KR20130054286A (ko) 2013-05-24
US20130102564A1 (en) 2013-04-25
IT1400232B1 (it) 2013-05-24
EA026568B1 (ru) 2017-04-28
IL222790A0 (en) 2012-12-31
CN102946862A (zh) 2013-02-27
EP2566457A1 (en) 2013-03-13
ITMI20100816A1 (it) 2011-11-08
EA201291191A1 (ru) 2013-04-30
AU2011250005A1 (en) 2012-11-29
MX2012012930A (es) 2013-05-20
NZ603476A (en) 2014-10-31
ZA201208949B (en) 2013-07-31
WO2011138262A1 (en) 2011-11-10
AU2011250005B2 (en) 2015-08-13
CL2012003090A1 (es) 2014-01-03
CA2798116A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
BR112015032432A2 (pt) Conjugado de oligonucleotídeo antisense, oligômero, composição farmacêutica, uso de um oligômero ou conjugado de oligonucleotídeo antisense ou composição farmacêutica, método de tratamento da hipercolesterolemia ou de distúrbios relacionados e método in vivo ou in vitro
BR112016009669A8 (pt) produtos farmacêuticos, método para tratar câncer e uso de um composto
WO2014194168A3 (en) Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
SV2010003674A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
BR112015015870A2 (pt) composição farmacêutica
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
BR112014010708A2 (pt) pró-fármaco à base de polietilenoglicol de adrenomedulina e utilização do mesmo
BR112018003892A2 (pt) ?composição farmacêutica e método para a redução da gordura?
BR112015015108A2 (pt) cateter com marcações para facilitar o alinhamento
BR102013022698B8 (pt) Éster de poliglicerol, processo para a produção do mesmo, seu uso e formulação cosmética ou farmacêutica
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112012019351A2 (pt) composição de combinação, que inclui como ingredientes ativos l-carnitina ou propionil l-carnitina, para a prevenção ou tratamento de insuficiência venosa crônica.
EA201690854A1 (ru) Фармацевтические композиции с гидратирующим и смазывающим действием
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
BR112016000092A2 (pt) nanopartículas lipídicas para a cicatrização de feridas
AR082653A1 (es) Composicion farmaceutica topica que comprende heparina
CL2012003006A1 (es) Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure